Neogen Stock Performance
| NEOG Stock | USD 5.71 0.13 2.23% |
The company secures a Beta (Market Risk) of -0.61, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Neogen are expected to decrease at a much lower rate. During the bear market, Neogen is likely to outperform the market. At this point, Neogen has a negative expected return of -0.54%. Please make sure to verify Neogen's potential upside, as well as the relationship between the daily balance of power and price action indicator , to decide if Neogen performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Neogen has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in July 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
Actual Historical Performance (%)
One Day Return (2.31) | Five Day Return 14.33 | Year To Date Return (52.22) | Ten Year Return (67.77) | All Time Return 1.2 K |
Last Split Factor 2:1 | Last Split Date 2021-06-07 |
1 | Acquisition by Borel James C of 6075 shares of Neogen at 13.58 subject to Rule 16b-3 | 04/01/2025 |
2 | Neogen Price Target Reduced by Piper Sandler Following Quarterly Results NEOG Stock News | 04/14/2025 |
3 | Acquisition by Borel James C of 35000 shares of Neogen at 4.894 subject to Rule 16b-3 | 04/24/2025 |
4 | Acquisition by Woteki Catherine E of 5770 shares of Neogen at 5.17 subject to Rule 16b-3 | 04/25/2025 |
5 | Disposition of 564 shares by Amy Rocklin of Neogen at 5.16 subject to Rule 16b-3 | 04/28/2025 |
6 | Reflecting On Medical Devices Supplies - Diversified Stocks Q1 Earnings Abbott Laboratories | 05/08/2025 |
7 | Neogen Stock Gains Following Strategic Alliance With Syngenta | 05/20/2025 |
8 | Neogen to Participate in the 45th Annual William Blair Growth S | 05/21/2025 |
9 | Neogen Trading 4.8 percent Higher - Heres What Happened - MarketBeat | 05/30/2025 |
10 | Neogen stock falls after Q4 update | 06/04/2025 |
11 | Neogen Launches Second Edition Environmental Monitoring Handbook to Elevate Food Safety Practices | 06/05/2025 |
12 | Neogen Corporation Investors Who Lost Money Contact Law Offices of Howard G. Smith About Securities Fraud Investigation | 06/06/2025 |
13 | NEOG Investors Have Opportunity to Join Neogen Corporation Fraud Investigation with the Schall Law Firm - marketscreener.com | 06/11/2025 |
| Begin Period Cash Flow | 163.2 M |
Neogen Relative Risk vs. Return Landscape
If you would invest 905.00 in Neogen on March 14, 2025 and sell it today you would lose (334.00) from holding Neogen or give up 36.91% of portfolio value over 90 days. Neogen is currently does not generate positive expected returns and assumes 6.1152% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than Neogen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neogen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neogen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neogen, and traders can use it to determine the average amount a Neogen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0882
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NEOG |
Estimated Market Risk
| 6.12 actual daily | 54 54% of assets are less volatile |
Expected Return
| -0.54 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Neogen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neogen by adding Neogen to a well-diversified portfolio.
Neogen Fundamentals Growth
Neogen Stock prices reflect investors' perceptions of the future prospects and financial health of Neogen, and Neogen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neogen Stock performance.
| Return On Equity | -0.17 | ||||
| Return On Asset | 0.0059 | ||||
| Profit Margin | (0.54) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 2 B | ||||
| Shares Outstanding | 217.04 M | ||||
| Price To Earning | 13.36 X | ||||
| Price To Book | 0.45 X | ||||
| Price To Sales | 1.37 X | ||||
| Revenue | 924.22 M | ||||
| Gross Profit | 442 M | ||||
| EBITDA | 182.6 M | ||||
| Net Income | (9.42 M) | ||||
| Cash And Equivalents | 347.71 M | ||||
| Cash Per Share | 3.22 X | ||||
| Total Debt | 906.24 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.07 X | ||||
| Book Value Per Share | 12.26 X | ||||
| Cash Flow From Operations | 35.26 M | ||||
| Earnings Per Share | (2.18) X | ||||
| Market Capitalization | 1.24 B | ||||
| Total Asset | 4.55 B | ||||
| Retained Earnings | 555.62 M | ||||
| Working Capital | 434.91 M | ||||
| Current Asset | 250 M | ||||
| Current Liabilities | 28.6 M | ||||
About Neogen Performance
By analyzing Neogen's fundamental ratios, stakeholders can gain valuable insights into Neogen's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Neogen has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neogen has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 172.59 | 201.93 | |
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Capital Employed | 0.01 | 0.01 |
Things to note about Neogen performance evaluation
Checking the ongoing alerts about Neogen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neogen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neogen generated a negative expected return over the last 90 days | |
| Neogen has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 924.22 M. Net Loss for the year was (9.42 M) with profit before overhead, payroll, taxes, and interest of 442 M. | |
| Neogen has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Transcript Aclaris Therapeutics, Inc. Presents at H.C. Wainwright HCWHome series, May-16-2025 01 - marketscreener.com |
- Analyzing Neogen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neogen's stock is overvalued or undervalued compared to its peers.
- Examining Neogen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neogen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neogen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neogen's stock. These opinions can provide insight into Neogen's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Neogen Stock analysis
When running Neogen's price analysis, check to measure Neogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neogen is operating at the current time. Most of Neogen's value examination focuses on studying past and present price action to predict the probability of Neogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neogen's price. Additionally, you may evaluate how the addition of Neogen to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |